ARHGDIA
ARHGDIA (Rho GDP dissociation inhibitor alpha, also known as RHOGDI or GDIA1) is a cytoplasmic regulator of Rho family GTPases. It holds Rho proteins in an inactive state by inhibiting the release of GDP, and so helps control Rho signalling. Browse Assay Genie's current range of ARHGDIA research reagents below, or read on for the biology behind the target.
ARHGDIA controls Rho protein homeostasis. It regulates the GDP/GTP exchange reaction of Rho proteins by inhibiting the dissociation of GDP from them, which in turn prevents the subsequent binding of GTP. In this way it keeps Rho proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool, where it regulates their stability and protects them from degradation.
The protein also takes part in the recycling and distribution of activated Rho GTPases within the cell. It extracts both inactive and activated molecules from membranes, owing to its exceptionally high affinity for their prenylated forms. Through this modulation of Rho proteins, ARHGDIA may play a role in regulating cell motility. In glioma cells, it inhibits migration and invasion by mediating signals from SEMA5A and PLXNB3 that lead to inactivation of RAC1.
The ARHGDIA gene belongs to the Rho GDI family and encodes the protein listed in UniProt as Rho GDP-dissociation inhibitor 1. Its previous name was Rho GDP dissociation inhibitor (GDI) alpha. According to the NCBI Gene summary, its activity matters in a variety of cellular processes, and expression of the gene may be altered in tumours. Mutations in the gene have been found in individuals with nephrotic syndrome, type 8, and alternate splicing produces multiple transcript variants. Mouse and rat both carry an orthologous gene, Arhgdia, which allows the pathway to be studied in rodent models.
ARHGDIA inhibits GDP release from Rho proteins and keeps them inactive, making it a central regulator of Rho family signalling.
Through Rho protein modulation it may regulate cell motility, and in glioma cells it inhibits migration and invasion via RAC1 inactivation.
Expression of the ARHGDIA gene may be altered in tumours, so the protein is of interest in studies of tumour cell behaviour.
Mutations in ARHGDIA have been found in individuals with nephrotic syndrome, type 8, linking the gene to kidney disease studies.
ARHGDIA inhibits the dissociation of GDP from Rho proteins and the subsequent binding of GTP, holding proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool. It also protects them from degradation and helps extract prenylated Rho GTPases from membranes.
ARHGDIA is also called RHOGDI and GDIA1. The HGNC name is Rho GDP dissociation inhibitor alpha, previously Rho GDP dissociation inhibitor (GDI) alpha, and UniProt lists the protein as Rho GDP-dissociation inhibitor 1. Alternate splicing gives multiple transcript variants.
Mutations in the ARHGDIA gene have been found in individuals with nephrotic syndrome, type 8, and its expression may be altered in tumours. Mouse and rat share an orthologous Arhgdia gene; check the datasheet of any product for its validated reactivity.
Rho GTPases, other Rho GDI family members and signalling partners that act alongside ARHGDIA.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P52565; product specifications from Assay Genie datasheets.